Following his education at Izmir Private Çakabey Highschool, Dr. Yandım obtained his BSc. in Molecular Biology and Genetics from Bilkent University. He conducted research at Harvard University Medical School as well as University of Texas Southwestern Medical Center, where he performed research on immunology and stem cell treatment. His emerging interest in gene control and epigenetics paved the way for him to do a PhD in this field at Imperial College London, where he was supported by a full scholarship from the Medical Research Council of United Kingdom. His findings on reversing gene dysregulation in an incurable form of ataxia led him to pursue an exploratory clinical trial. He published the results of this study in "The Lancet", which is one of the top-ranked scientific journals in the world. He continued his postdoctoral studies also in London at the Institute of Cancer Research, where he studied signal transduction in cancer. He is currently focused on revealing the interplay between repetitive DNA and cancer as well as aging. He also conducts studies on interdisciplinary biology and next-generation computational drug design.
Dr. Yandım is an honorary associate at Izmir Biomedicine and Genome Center (iBG).